Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth driven by its health sweetener products, particularly allulose, and benefits from its stake in a rural commercial bank, as well as the depreciation of the RMB [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and health sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from health sweeteners, and 3.91% from other products [8]. - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8]. - The company was established on December 30, 2005, and went public on April 21, 2021 [8]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and innovation [4]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the RMB [4]. Group 4: Stock Performance and Trading Activity - On September 30, the company's stock rose by 0.20%, with a trading volume of 64.54 million yuan and a turnover rate of 0.77%, bringing the total market capitalization to 8.43 billion yuan [1]. - The average trading cost of the stock is 20.44 yuan, with the current price approaching a resistance level of 20.15 yuan, indicating potential for a price correction if this level is not surpassed [7]. - The main capital inflow for the day was 461,300 yuan, with no significant trends in capital movement observed [5][6].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [1][2][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and healthy sweetener products, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8]. - As of August 29, the company had 12,700 shareholders, a decrease of 0.43% from the previous period, with an average of 33,056 circulating shares per shareholder, an increase of 0.43% [8]. - The company has achieved a revenue of 649 million yuan in the first half of 2025, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. Group 2: Financial Performance - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial benefits [3]. Group 3: Market Position and Trends - The company is recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and market share [4]. - The company benefits from a 60.62% share of overseas revenue, positively impacted by the depreciation of the RMB [4]. Group 4: Stock Performance and Investor Sentiment - On September 29, the company's stock price fell by 1.77%, with a trading volume of 61.92 million yuan and a turnover rate of 0.73%, leading to a total market capitalization of 8.413 billion yuan [1]. - The stock has an average trading cost of 20.43 yuan, with recent buying activity indicating weak accumulation, and the stock price is approaching a resistance level of 20.11 yuan [7].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing positive market movements due to its involvement in the rare sugar industry, particularly with allulose, and benefits from its stake in a rural commercial bank amidst the depreciation of the RMB [2][3][4]. Company Overview - Shandong Bailong Chuangyuan was established on December 30, 2005, and went public on April 21, 2021. The company specializes in the research, production, and sales of prebiotic products, dietary fiber products, and healthy sweeteners [8]. - The company's main revenue sources are dietary fiber series (54.15%), prebiotic series (28.00%), healthy sweeteners (13.57%), and others (3.91%) [8]. Financial Performance - For the first half of 2025, the company achieved a revenue of 649 million yuan, representing a year-on-year growth of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which is expected to benefit from the depreciation of the RMB [3][4]. - It has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which is a prestigious title for small and medium-sized enterprises in China [4]. Stock Performance - On September 24, the company's stock rose by 1.08%, with a trading volume of 121 million yuan and a turnover rate of 1.40%, bringing the total market capitalization to 8.631 billion yuan [1]. - The average trading cost of the stock is 20.43 yuan, with the current price near a support level of 20.53 yuan [7]. Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Penghua New Emerging Industry Mixed Fund and Hong Kong Central Clearing Limited, with some new entrants among the top ten shareholders [10].

Group 1 - The company held its fourth board meeting on September 23, 2025, with all seven directors present, and the meeting was deemed legal and effective [2][4]. - The board approved several resolutions, including extending the validity period for issuing convertible bonds to unspecified objects, which will now last until October 10, 2026 [3][32]. - The board also approved a special report on the use of previously raised funds, with unanimous support from all directors [6][7]. Group 2 - The company plans to apply for an additional bank credit facility, increasing the total credit limit to 1.2 billion RMB, which includes a previous limit of 800 million RMB and an additional 400 million RMB [10][29]. - A temporary shareholders' meeting is scheduled for October 9, 2025, to discuss the approved resolutions, with provisions for both on-site and online voting [12][14]. - The company will utilize a reminder service to ensure that small and medium investors are informed and can participate in the voting process [13].

证券代码：605016 证券简称：百龙创园 公告编号：2025-061 山东百龙创园生物科技股份有限公司 关于提请股东会延长授权董事会及其授权人士全权办理 公司向不特定对象发行可转换公司债券相关事宜的公告 公司于 2024 年 10 月 11 日召开 2024 年第三次临时股东大会，审议通过了《关于 公司向不特定对象发行可转换公司债券方案的议案》《关于提请股东大会授权董事会 及其授权人士全权办理公司向不特定对象发行可转换公司债券相关事宜的议案》等议 案，根据上述股东大会决议，股东大会授权董事会及其授权人士在符合相关法律、法 规的前提下全权办理与本次发行有关的相关事宜，有效期为自公司 2024 年第三次临 时股东大会审议通过本次发行方案之日起十二个月。 鉴于上述授权的有效期即将到期，公司向不特定对象发行可转换公司债券工作尚 未完成，为保证公司本次发行有关事宜的顺利推进，公司拟将授权董事会及其授权人 士全权办理公司向不特定对象发行可转换公司债券相关事宜的有效期自原有效期届满 之日起延长十二个月，即有效期延长至 2026 年 10 月 10 日。除延长上述有效期外， 公司股东会授权董事会及其授权人士全权办理公司向不 ...

关于新增申请银行综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东百龙创园生物科技股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开了第四届董事会第三次会议，审议通过《关于新增申请银行综合授信额度的议 案》，具体内容如下： 证券代码：605016 证券简称：百龙创园 公告编号：2025-062 山东百龙创园生物科技股份有限公司 特此公告。 山东百龙创园生物科技股份有限公司董事会 2025 年 9 月 24 日 根据公司的业务发展需要，为保障公司及下属子公司正常生产经营活动，节约公 司申请银行授信的审批成本，缩短银行授信审批时间，公司拟在 2025 年 4 月 29 日召 开的第三届董事会第十五次会议审议通过的 8 亿元基础上，再新增 4 亿元的融资额度， 累计综合授信额度不超过人民币 12 亿元（含存量）。授信额度最终以银行实际审批 的授信额度为准。 以上授信额度不等于公司的实际融资金额，实际融资金额在授信额度内以具体合 作银行与各公司（含子公司）实际发生的融资金额为准。授信种 ...

| 开户银行 | 银行账号 | 账户类别 | 募集资金原始 | 截止日余 | 备注 | | --- | --- | --- | --- | --- | --- | | | | | 存入金额 | 额 | | | 中国建设银行股份有 | 37050184630 | 非预算单位专用 | 105,217,160.06 | | 已注销 | | 限公司禹城支行 | 100001390 | 存款账户 | | | | | 中国农业银行股份有 | 15785101040 | 非预算单位专用 | 171,100,000.00 | | 已注销 | | 限公司禹城市支行 | 025527 | 存款账户 | | | | | 德州银行股份有限公 | 80901320101 | 非预算单位专用 | 80,000,000.00 | | 已注销 | | 司禹城支行 | 421028954 | 存款账户 | | | | | 德州银行股份有限公 | 80901320101 | 非预算单位专用 | 49.900.000.00 | | 已注销 | | 司禹城支行 | 421028961 | 存款账户 | | | | | 合 计 | | | 406,2 ...

山东百龙创园生物科技股份有限公司 前次募集资金使用情况 鉴证报告 致同会计师事务所 (特殊普通合伙) 目 录 前次募集资金使用情况鉴证报告 公司前次募集资金使用情况报告 1-3 前次募集资金使用情况对照表 4 前次募集资金投资项目实现效益情况对照表 5 rant Thornton स्य |三| 前次募集资金使用情况鉴证报告 致同专字(2025)第 410A020217 号 山东百龙创园生物科技股份有限公司全体股东: 我们审核了后附的山东百龙创园生物科技股份有限公司(以下简称百龙 创园公司)截至2025年6月30日的前次募集资金使用情况报告、前次募集资 金使用情况对照表和前次募集资金投资项目实现效益情况对照表。按照中国 证监会《监管规则适用指引 -- 发行类第 7号》的规定编制上述前次募集资 金使用情况报告及对照表是百龙创园公司董事会的责任,我们的责任是在实 施鉴证程序的基础上对百龙创园公司董事会编制的上述前次募集资金使用情 况报告及对照表提出鉴证结论。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号 -- 历史财务信 息审计或审阅以外的鉴证业务》的规定计划和实施鉴证工作,以合理确信上 述前次募集资 ...

证券代码：605016 证券简称：百龙创园 公告编号：2025-060 山东百龙创园生物科技股份有限公司 山东百龙创园生物科技股份有限公司董事会 2025 年 9 月 24 日 1 山东百龙创园生物科技股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开了第四届董事会第三次会议，审议通过《关于延长公司向不特定对象发行可转换 公司债券股东会决议有效期的议案》，具体内容如下： 公司于 2024 年 10 月 11 日召开 2024 年第三次临时股东大会，审议并通过了《关 于公司向不特定对象发行可转换公司债券方案的议案》，根据上述股东大会决议，公 司本次向不特定对象发行可转换公司债券（以下简称"本次发行"）的股东大会决议 有效期为自公司 2024 年第三次临时股东大会审议通过本次发行方案之日起十二个月。 鉴于本次发行的股东会决议有效期即将到期，为保证公司本次发行工作持续性和 有效性，确保本次发行有关事宜的顺利推进，公司拟将本次发行的股东会决议有效期 自原有效期届满之日起延长十二个月，即有效期延长至 2026 年 10 月 10 日。除上述 延长本次发行股东会决议有效期外，本次发行方案的其他事项和 ...

证券代码：605016 证券简称：百龙创园 公告编号：2025-064 山东百龙创园生物科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为更好的服务广大中小投资者，确保有投票意愿的中小投资者能够及时 参会、及时投票。公司拟使用上证所信息网络有限公司（以下简称"上证信息"） 提供的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记 日的股东名册主动提醒股东参会投票，向每一位投资者主动推送股东会参会邀 请、议案情况等信息。投资者在收到智能短信后，可根据使用手册（下载链接： https://vote.sseinfo.com/i/yjt_help.pdf）的提示步骤直接投票，如遇拥堵 等情况，仍可通过原有的交易系统投票平台和互联网投票平台进行投票。 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第三次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 股东会召开日期：2 ...